The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers
Not Applicable
Completed
- Conditions
- Interaction
- Interventions
- Registration Number
- NCT01482117
- Lead Sponsor
- Inje University
- Brief Summary
The aim of this study is to investigate the effects of genetic polymorphisms on pharmacokinetic and pharmacodynamic interactions of clopidogrel and cilostazol in Korean healthy adult volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 28
Inclusion Criteria
- Healthy male subject whose CYP2C19 genotype was determined
Exclusion Criteria
- Subject who has abnormal laboratory test results
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Clopidogrel Clopidogrel/Cilostazol single oral administration of 300mg of clopidogrel Cilostarole Clopidogrel single oral administration of 100mg of cilostazole Cilostarole Cilostazol single oral administration of 100mg of cilostazole Cilostarole Clopidogrel/Cilostazol single oral administration of 100mg of cilostazole Clopidogrel/Cilostazol Clopidogrel single oral administration of 300mg clopidogrel and 100mg cilostazol Clopidogrel/Cilostazol Clopidogrel/Cilostazol single oral administration of 300mg clopidogrel and 100mg cilostazol Clopidogrel Clopidogrel single oral administration of 300mg of clopidogrel Clopidogrel Cilostazol single oral administration of 300mg of clopidogrel Clopidogrel/Cilostazol Cilostazol single oral administration of 300mg clopidogrel and 100mg cilostazol
- Primary Outcome Measures
Name Time Method Maximum concentration(Cmax), Area under the concentration(AUC), Inhibition of platelet aggregation(IPA) up to 24 hours 9 or 11 point blood sampling according to the interventions
- Secondary Outcome Measures
Name Time Method